Skip to main content
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.58
+0.96 (8.26%)
At close: Mar 6, 2026, 4:00 PM EST
12.81
+0.23 (1.83%)
After-hours: Mar 6, 2026, 5:19 PM EST

Entrada Therapeutics Revenue

In the year 2025, Entrada Therapeutics had annual revenue of $25.42M, down -87.94%. Entrada Therapeutics had revenue of $1.30M in the quarter ending December 31, 2025, a decrease of -96.53%.

Revenue (ttm)
$25.42M
Revenue Growth
-87.94%
P/S Ratio
17.82
Revenue / Employee
$167,243
Employees
152
Market Cap
452.88M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202525.42M-185.36M-87.94%
Dec 31, 2024210.78M81.77M63.38%
Dec 31, 2023129.01M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Vanda Pharmaceuticals 216.11M
REGENXBIO 170.44M
Century Therapeutics 113.34M
Assembly Biosciences 37.19M
Lineage Cell Therapeutics 14.56M
4D Molecular Therapeutics 120.00K
Altimmune 41.00K
vTv Therapeutics 17.00K
Revenue Rankings

TRDA News

More News